【摘要】 目的评价新一代氟喹诺酮类药物(FQNs)莫西沙星(MXFX)对耐多药肺结核病(MDR-PTB)的临床疗效及安全性。方法将MDR-PTB患者随机分为两组,治疗组用含MXFX方案,对照组用含司帕沙星(SPFX)方案,疗程12个月。结果满疗程时可以评价疗效的治疗组36例、对照组35例。满2~3个月时痰菌阴转率达到75.0%、80.3%,对照组为51.4%、68.6%,2组比较差异显著(P<0.05),4个月以后各期痰菌阴转率也均高于对照组,但经统计学处理差异无显著性(P>0.05)。疗程末治疗组痰菌阴转率、病灶吸收、空洞闭合率分别为91.7%、88.9%、54.5%,均高于对照组相应指标82.9%、80.0%、40.6%,但2组比较差异无显著性(P>0.05),药物不良反应治疗组15.4%,低于对照组35.0%,经统计学处理差异显著(P<0.05)。结论MXFX是一种安全、有效的抗MDR-PTB的药物。更多还原

【Abstract】 Objective To compare and evaluate the therapeuticeffect and safety of moxifloxacin on multiple drug resistant pulmonary tuberculosis(MDR-PTB).Methods 81 patients with MDR-PTB were randomlydivided into trial group and control group.The patients in trial group were treated with moxifloxacin containing regimen;the patients in control group were treated with sparfloxacin-containing regimen,with a treatment course of 12 months forboth groups.Results At the end of the treatment course,36 patients in trial group and 35 patients in control group could be evaluated.In full of 2 and 3 months,the sputums negative conversion rates were 75%,80.3% in trialgroup,which were significantly higher than 51.4%,60.0% i control group(P<0.05),Four months later,the sputum negativeconversion rates in trial group were higher than those of control group,but there was no significant difference between the two groups(P>0.05).At end of treatment course,the sputums negative conversion rate,focus absorption rate and cavity closing rate were 91.7%,88.9%,54.5% respectively in trial group,which were significantly higher than 82.9%,80.0.%,40.6%in control group(P>0.05),but theree were no significant differences between two groups(P>0.05).Adverse reaction intrial group was 15.4%,which was significantly lower than 35.0% in control group(P<0.05).Conclusion Moxiflocacin-containing regimen is effective and safe drug in the treatment of MDR-PTB.更多还原